Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by MetzGERon Oct 18, 2023 2:26pm
101 Views
Post# 35689487

RE:RE:RE:Questions

RE:RE:RE:QuestionsIf i was a Big company like Shiseido i wouldnt put my scientist to hair conferences Holding speeches about the Cell therapy hair Regeneration (= RCH-01) If i would know that the trials failed and the prodouct Never will be launched.

if i was The CEO of Shiseido and knew that RCH-01 is sh1t then i wouldnt Go into partnership in 08/2023 with a Special company Helping to prepare for commercial Launch in the clinics.

You always Want to certainty, Ingiboy. You Want Shiseido saying "We will commercialize hair Regeneration in Decembre 2023" But you wont get this now. We Can be happy that there Are 3 Big Hints in 2023 that Shiseido is convinced By the product. I was very relieved After finding this hints. It is now speculating. If we always get certainity investing would be very Easy.
fuerhermore we wont get certainity How Andrew and Jamie will strategy the Shiseido Deal. It wouldnt be clever to publish that.
But i am with you they have to be 100% transparente of their strategy to bring the Dermal injector to US Market with MainPointe 

<< Previous
Bullboard Posts
Next >>